Consumer Protection in AI-Driven Pharmaceutical Recommendation Bias Controls

Introduction

AI-driven pharmaceutical recommendation systems use artificial intelligence, algorithms or clinical decision-support tools to recommend medicines, treatment options or pharmaceutical products. These systems may analyse symptoms, medical history, laboratory results, medication history and other patient information.

Such technology can support healthcare professionals, but it also creates consumer-protection concerns when recommendations are affected by biased data, pharmaceutical commercial interests, incomplete medical information or inappropriate algorithmic design.

The central principle is that an AI system should recommend medicines based on clinically relevant and reliable information, rather than secretly favouring a particular pharmaceutical company, product or commercially beneficial medicine.

Meaning of Pharmaceutical Recommendation Bias

Algorithmic bias occurs when an AI system systematically favours or disadvantages particular medicines, pharmaceutical companies or groups of patients without an appropriate clinical justification.

For example, an AI system might repeatedly recommend Medicine A over equally suitable alternatives because its underlying data or optimisation process favours Medicine A.

Bias can arise from:

incomplete training data;

biased clinical datasets;

pharmaceutical sponsorship;

commercial ranking arrangements;

inaccurate patient information;

inappropriate variables;

outdated medical evidence; or

poor algorithmic design.

Consumer Right to Unbiased Medical Information

Patients have an important interest in receiving accurate, relevant and non-misleading medical information.

If an AI system recommends a particular medicine, the recommendation should be based on appropriate clinical considerations rather than hidden commercial incentives.

This becomes especially important where the patient or healthcare professional assumes that the recommendation is independent.

Pharmaceutical Commercial Influence

A significant concern is the possibility of pharmaceutical companies influencing AI recommendations.

For example, a pharmaceutical company could have a commercial relationship with the organisation operating an AI platform. If that relationship influences which medicine the system recommends, the platform should not present the recommendation as completely independent.

The existence of a commercial relationship does not automatically establish unlawful conduct. The important questions are whether the relationship influences the recommendation, whether it is properly disclosed and whether the resulting recommendation is misleading or clinically inappropriate.

Recommendation vs Advertisement

A consumer can reasonably interpret a medical recommendation differently from an advertisement.

An advertisement is normally understood to have a promotional purpose. A personalised recommendation may instead be perceived as professional or clinically objective advice.

Therefore, an AI system should not disguise pharmaceutical promotion as independent medical advice.

This distinction is particularly important where the recommendation is personalised according to a patient's medical information.

Transparency of AI Recommendations

Consumers should receive meaningful information about the role of AI in pharmaceutical recommendations.

The patient should be able to understand whether:

AI was used;

the recommendation was reviewed by a healthcare professional;

commercial relationships exist;

alternative medicines were considered; and

the recommendation is advisory or definitive.

The patient does not necessarily need access to the algorithm's source code. The objective is meaningful transparency about the system's role and important influences.

Clinical Evidence

A responsible pharmaceutical recommendation system should rely on appropriate and current medical evidence.

The system should be monitored to ensure that recommendations do not continue to rely on outdated medical information.

This is particularly important because pharmaceutical evidence can change as new clinical research, safety information and treatment guidelines become available.

Bias from Training Data

AI systems learn patterns from data. If the underlying dataset contains historical bias, the algorithm may reproduce that bias.

For example, if the training data disproportionately represents certain patient populations, the system may perform less accurately for other populations.

Therefore, pharmaceutical recommendation systems should be evaluated using appropriately representative data and should be periodically tested for differences in performance.

Patient-Specific Bias

Bias may also occur when the system fails to properly account for relevant patient characteristics.

A medicine that is appropriate for one patient may not be appropriate for another because of differences in medical history, allergies, existing medication, age or other clinically relevant circumstances.

Therefore, a recommendation system should not rely on a generic assumption that one medicine is suitable for everyone.

Drug Interaction Risks

AI systems should appropriately consider medication interactions where relevant.

If a recommendation system fails to consider an existing medicine being taken by the patient, the resulting recommendation may create a safety concern.

This demonstrates why complete and accurate patient information is essential to reliable pharmaceutical recommendations.

Human Oversight

Human oversight is one of the most important safeguards.

A strong framework should follow:

AI Analysis → Healthcare Professional Review → Clinical Decision

rather than:

AI Recommendation → Automatic Prescription

A qualified healthcare professional should be able to reject or modify an AI recommendation when it is inconsistent with the patient's circumstances.

Right to Question the Recommendation

Patients should have an opportunity to ask why a particular medicine was recommended.

Relevant questions may include:

Why was this medicine selected?

Were alternatives considered?

Is the recommendation based on current medical evidence?

Does the system have a commercial relationship with the manufacturer?

Is the recommendation reviewed by a healthcare professional?

The purpose is to protect patient autonomy and informed decision-making.

Conflict of Interest

A conflict of interest can arise when the organisation operating the recommendation system benefits financially from a particular pharmaceutical product.

For example, if Product A generates greater commercial revenue than Product B, the system should not secretly optimise recommendations toward Product A while claiming to provide independent clinical recommendations.

A proper governance framework should identify, manage and disclose material conflicts.

Consumer Protection Act, 2019

The Consumer Protection Act, 2019 provides a general framework concerning consumer rights, unfair trade practices, misleading representations and deficiency in services.

If a healthcare platform makes misleading claims about the independence, effectiveness or accuracy of an AI pharmaceutical recommendation, consumer-protection principles may become relevant depending on the circumstances.

For example, describing a commercially influenced recommendation as an entirely independent medical recommendation could raise concerns if the representation materially misleads the consumer.

However, an incorrect recommendation does not automatically establish consumer-law liability. The actual service, representations, professional conduct, applicable regulations and circumstances must be examined.

Drugs and Medical Regulation

Pharmaceutical recommendations operate within India's broader framework governing medicines and healthcare.

Where AI is used as part of a medical device or clinical decision-support system, the applicable medical-device regulatory requirements may also become relevant depending on the system's intended purpose and functionality.

The use of AI does not remove the existing legal requirements applicable to medicines, healthcare professionals or medical technologies.

Prescription Responsibility

An AI system should not become an independent prescriber merely because it is capable of generating a medicine recommendation.

Where prescription decisions require professional medical judgment, the responsible healthcare professional should retain appropriate control over the final decision.

This creates an important accountability chain:

AI Recommendation → Professional Assessment → Prescription

Data Protection

Pharmaceutical recommendation systems may process highly sensitive medical information.

The Digital Personal Data Protection Act, 2023 provides India's broader framework for digital personal-data processing where applicable.

Organisations should therefore consider requirements concerning lawful processing, security, purpose limitation, data minimisation and grievance handling.

The use of medical information to personalise pharmaceutical recommendations should be appropriately governed.

Accuracy of Patient Data

Algorithmic recommendations are only as reliable as the information supplied to the system.

For example:

Incorrect Medical History → Incorrect AI Assessment → Inappropriate Recommendation

Patients should therefore have appropriate mechanisms for identifying and correcting materially inaccurate information.

Bias Auditing

A robust AI pharmaceutical recommendation system should undergo regular bias testing.

Audits can examine whether:

certain medicines are systematically favoured;

pharmaceutical relationships influence recommendations;

recommendations differ unnecessarily between patient groups;

outdated evidence remains embedded in the model;

error rates differ between populations; and

commercial incentives affect ranking or recommendation outcomes.

The objective is not to ensure that every patient receives the same medicine. The objective is to ensure that differences are supported by legitimate clinical considerations.

Independent Auditing

Independent assessment can strengthen confidence in the recommendation system.

An independent audit may examine:

training data;

clinical evidence;

model methodology;

pharmaceutical relationships;

recommendation patterns;

safety risks;

error rates; and

complaint records.

Independence is particularly important where the AI system is operated by an organisation with financial interests in pharmaceutical products.

Audit Trails

The organisation should maintain appropriate records concerning:

patient information used;

model versions;

recommendation outputs;

relevant clinical evidence;

changes to the system;

human overrides;

pharmaceutical relationships; and

consumer complaints.

Audit trails allow an organisation to investigate how a particular recommendation was produced.

Right to Human Review

Where a consumer disputes an AI-generated pharmaceutical recommendation, an appropriate mechanism for professional review should be available.

A practical process is:

Patient Concern → Recommendation Review → Professional Assessment → Alternative Recommendation Where Appropriate

This prevents the AI output from becoming an unquestionable medical decision.

Case-Law Position

There is currently no comprehensive Indian Supreme Court judgment specifically establishing a legal doctrine for bias controls in AI-driven pharmaceutical recommendation systems.

Therefore, existing medical-negligence and consumer cases should not be presented as direct precedents concerning modern AI pharmaceutical recommendation algorithms.

The legal position instead has to be understood through broader principles concerning medical negligence, consumer protection, informed decision-making, privacy, pharmaceutical regulation and professional accountability.

Indian Medical Association v. V.P. Shantha

In Indian Medical Association v. V.P. Shantha, the Supreme Court recognised that medical services can, in appropriate circumstances, fall within consumer-protection law.

This principle is relevant because digital or AI-assisted healthcare does not automatically fall outside consumer protection simply because technology is involved.

However, the case does not specifically address AI pharmaceutical recommendations.

Jacob Mathew v. State of Punjab

In Jacob Mathew v. State of Punjab, the Supreme Court examined principles concerning medical negligence and the standard of reasonable professional care.

The case is relevant by analogy because a healthcare professional using an AI recommendation system remains subject to appropriate professional standards.

The use of an AI tool should not automatically excuse a healthcare professional from exercising reasonable medical judgment.

K.S. Puttaswamy v. Union of India

The Supreme Court's privacy jurisprudence in K.S. Puttaswamy v. Union of India recognised privacy as a fundamental right and connected it with dignity and individual autonomy.

This is relevant because pharmaceutical recommendation systems can process sensitive medical information.

The case does not establish specific AI pharmaceutical rules, but its principles support the importance of protecting patient autonomy and medical information.

Accountability for Third-Party AI Providers

Healthcare organisations may obtain AI recommendation technology from external companies.

This does not automatically remove responsibility from the organisation providing healthcare to the consumer.

Appropriate oversight should exist concerning:

AI vendors;

data providers;

clinical evidence;

system updates;

cybersecurity;

recommendation accuracy; and

consumer complaints.

Technology outsourcing should not create an accountability gap.

Redress Mechanism

A consumer who believes that an AI pharmaceutical recommendation was biased or inappropriate should have an accessible grievance process.

A practical mechanism is:

Consumer Complaint → Data and Recommendation Review → Professional Assessment → Correction or Appropriate Remedy

The appropriate remedy will depend on the nature of the service, applicable regulations and the circumstances of the individual case.

Conclusion

AI-driven pharmaceutical recommendation systems can improve healthcare decision-making, but they should not become hidden channels for pharmaceutical promotion or commercially influenced treatment recommendations.

Consumer protection requires clinical accuracy, transparency, conflict-of-interest controls, representative data, bias auditing, human professional oversight, privacy protection and effective grievance mechanisms.

The key principle is:

AI may assist in recommending medicines, but clinical relevance and patient welfare should remain more important than commercial preference.